Founded in 2023, Shanghai-based Allink Biotherapeutics is a clinical-stage biotechnology company focused on creating advanced ADCs and multi-specific antibody therapies. Its two lead candidates, ALK201 (an FGFR2b-targeted ADC) and ALK202 (an EGFR/cMET bispecific ADC), are already in global Phase I trials and have shown encouraging early efficacy and safety signals across multiple tumor types. The firm is pursuing a biomarker-guided strategy and plans to initiate combination studies to broaden the clinical reach of these assets and prepare them for pivotal trials. Beyond its ADC programs, AllinkBio is building a proprietary masked T-cell engager platform and a pipeline of first-in-class bi- and multi-specific antibodies aimed at underserved patient populations. The company emphasizes rapid R&D execution and platform innovation to maintain competitive differentiation. The recent $47 million Series A extension financing underscores strong investor confidence and provides the capital required to advance lead programs and expand discovery efforts.

Total raised

$89M

Funding rounds

2

Latest round

Series A

Latest activity

Dec 2025